|  |  | 

India Top Headlines

Government studies the possibility of incorporating 3 or 4 more companies to increase the production of DRDO Covid drugs | India News


NEW DELHI: In the midst of the ongoing pandemic, the government is considering the participation of three or four more companies to increase the production of the drug 2DG, developed by the DRDO for the treatment of Covid-19 and end its shortage.
“After the launch of the medicine on Monday, the demand for the drug is very high as many patients and their families are sharing positive experiences, “said government sources.
However, due to limited production capacity, many patients have not been able to obtain the drug despite having prescriptions from doctors, they said.
In view of the situation, we are considering allowing 3 or 4 more companies to produce the drug using the DRDO patent for the drug, the sources said.
In the first batch, the manufacturers had supplied just 10,000 sachets and the supply is likely to improve only in mid-June.
From the first batch of the drug, sachets were distributed to the Indian Institute of Medical Sciences and the Director General of the Armed Forces Medical Services, while some were kept as a reserve.
The drug, 2-DG, has been developed by DRDO’s Institute of Nuclear Medicine and Allied Sciences (INMAS), in collaboration with Dr. Reddy’s Laboratories, Hyderabad. Results from clinical trials have shown that this molecule helps in faster recovery in hospitalized patients and reduces dependence on supplemental oxygen.
A higher proportion of patients treated with 2-DG have shown negative conversion by RT-PCR in patients with Covid. The drug will be of immense benefit to people suffering from Covid-19.

Reference page